Browse COPS6

Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=The interaction with HIV-1 Vpr protein possibly leads its translocation to a perinuclear region.
Domain PF01398 JAB1/Mov34/MPN/PAD-1 ubiquitin protease
PF13012 Maintenance of mitochondrial structure and function
Function

Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITPK1 and IRF8, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively. Has some glucocorticoid receptor-responsive activity. Stabilizes COP1 through reducing COP1 auto-ubiquitination and decelerating COP1 turnover rate, hence regulates the ubiquitination of COP1 targets.

> Gene Ontology
 
Biological Process GO:0000338 protein deneddylation
GO:0000715 nucleotide-excision repair, DNA damage recognition
GO:0006283 transcription-coupled nucleotide-excision repair
GO:0006289 nucleotide-excision repair
GO:0010388 cullin deneddylation
GO:0070646 protein modification by small protein removal
Molecular Function -
Cellular Component GO:0008180 COP9 signalosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-5696394: DNA Damage Recognition in GG-NER
R-HSA-73894: DNA Repair
R-HSA-6781823: Formation of TC-NER Pre-Incision Complex
R-HSA-5696399: Global Genome Nucleotide Excision Repair (GG-NER)
R-HSA-199991: Membrane Trafficking
R-HSA-5696398: Nucleotide Excision Repair
R-HSA-6781827: Transcription-Coupled Nucleotide Excision Repair (TC-NER)
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between COPS6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of COPS6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of COPS6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2490.329
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3160.919
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2020.93
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1850.502
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1730.923
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6350.775
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.130.746
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4180.818
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1920.924
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0320.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0970.976
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2130.000695
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of COPS6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COPS6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COPS6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COPS6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COPS6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of COPS6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between COPS6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCOPS6
NameCOP9 signalosome subunit 6
Aliases MOV34-34KD; CSN6; COP9 subunit 6 (MOV34 homolog, 34 kD); COP9 constitutive photomorphogenic homolog subunit ......
Chromosomal Location7q22.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting COPS6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.